Patents Assigned to TheraSyn Sensors, Inc.
  • Patent number: 11737976
    Abstract: The invention broadly comprises a chemical composition including a plurality of cholesteryl esters arranged to form a vesicle. In several embodiments, all of the plurality of cholesteryl esters have a same molecular length, which in some embodiments provides a vesicle having a generally smooth outer surface, while in other embodiments, a portion of the plurality of cholesteryl esters have different molecular lengths, which in some embodiments provides a vesicle having a generally irregular outer surface. In yet further embodiments, a shape of the vesicle is selected from the group consisting of spherical, oval, disc-like, tubular and polyhedral shapes, and in yet other embodiments, a wall of the vesicle is selected from the group consisting of a monolayer and a bilayer. In still further embodiments, the chemical composition further includes a polyethylene glycol coat of mixed polymer size.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: August 29, 2023
    Assignee: THERASYN SENSORS, INC.
    Inventor: Mary P. McCourt
  • Patent number: 11633364
    Abstract: The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (“cholestosome”) consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.
    Type: Grant
    Filed: June 2, 2021
    Date of Patent: April 25, 2023
    Assignee: THERASYN SENSORS, INC.
    Inventors: Jerome J. Schentag, Mary P. McCourt, Lawrence Mielnicki, Julie Hughes
  • Patent number: 11052052
    Abstract: The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (“cholestosome”) consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: July 6, 2021
    Assignee: THERASYN SENSORS, INC.
    Inventors: Jerome J. Schentag, Mary P. McCourt, Lawrence Mielnicki, Julie Hughes
  • Publication number: 20200069161
    Abstract: The present invention may be embodied as a retrievable device capable of sensing one or more properties of an individual (e.g., chemical or physical parameters). In use, the retrievable device can continuously determine the chemical concentrations within the vaginal tract. An embodiment of the retrievable device comprises a first housing having a light source and an image capture device, a second housing removably connected to the first housing and having a sensor, and a fitting for retrieving the device. The sensor may be an analyte sensor configured to obtain at least one measurement of a concentration of an analyte in a fluid. The analyte sensor comprises a sensor substance in a sol-gel material so the sensor substance reversibly interacts with an analyte of interest. In addition, the retrievable device can be configured to determine different physical parameters and re-implanted.
    Type: Application
    Filed: July 15, 2019
    Publication date: March 5, 2020
    Applicant: TheraSyn Sensors, Inc.
    Inventors: Jerome J. Schentag, Frank V. Bright, David T. D'Andrea
  • Patent number: 10369114
    Abstract: The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (“cholestosome”) consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: August 6, 2019
    Assignee: THERASYN SENSORS, INC.
    Inventors: Jerome J. Schentag, Mary P. McCourt, Lawrence Mielnicki, Julie Hughes
  • Patent number: 10349820
    Abstract: The present invention may be embodied as a retrievable device capable of sensing one or more properties of an individual (e.g., chemical or physical parameters, etc.) In use, the retrievable device can continuously determine the chemical concentrations within the vaginal tract. An embodiment of the retrievable device comprises a first housing having a light source and an image capture device, a second housing removably connected to the first housing and having a sensor, and a fitting for retrieving the device. The sensor may be an analyte sensor configured to obtain at least one measurement of a concentration of an analyte in a fluid. The analyte sensor comprises a sensor substance in a sol-gel material so the sensor substance reversibly interacts with an analyte of interest. In addition, the retrievable device can be configured to determine different physical parameters and re-implanted.
    Type: Grant
    Filed: July 12, 2011
    Date of Patent: July 16, 2019
    Assignee: TheraSyn Sensors, Inc.
    Inventors: Jerome J. Schentag, Frank V. Bright, David T. D'Andrea
  • Publication number: 20190060236
    Abstract: The invention broadly comprises a chemical composition including a plurality of cholesteryl esters arranged to form a vesicle. In several embodiments, all of the plurality of cholesteryl esters have a same molecular length, which in some embodiments provides a vesicle having a generally smooth outer surface, while in other embodiments, a portion of the plurality of cholesteryl esters have different molecular lengths, which in some embodiments provides a vesicle having a generally irregular outer surface. In yet further embodiments, a shape of the vesicle is selected from the group consisting of spherical, oval, disc-like, tubular and polyhedral shapes, and in yet other embodiments, a wall of the vesicle is selected from the group consisting of a monolayer and a bilayer. In still further embodiments, the chemical composition further includes a polyethylene glycol coat of mixed polymer size.
    Type: Application
    Filed: August 31, 2018
    Publication date: February 28, 2019
    Applicant: TheraSyn Sensors, Inc.
    Inventor: Mary P. McCourt
  • Patent number: 10092516
    Abstract: The invention broadly comprises a chemical composition including a plurality of cholesteryl esters arranged to form a vesicle. In several embodiments, all of the plurality of cholesteryl esters have a same molecular length, which in some embodiments provides a vesicle having a generally smooth outer surface, while in other embodiments, a portion of the plurality of cholesteryl esters have different molecular lengths, which in some embodiments provides a vesicle having a generally irregular outer surface. In yet further embodiments, a shape of the vesicle is selected from the group consisting of spherical, oval, disc-like, tubular and polyhedral shapes, and in yet other embodiments, a wall of the vesicle is selected from the group consisting of a monolayer and a bilayer. In still further embodiments, the chemical composition further includes a polyethylene glycol coat of mixed polymer size.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: October 9, 2018
    Assignee: THERASYN SENSORS, INC.
    Inventor: Mary P. McCourt
  • Publication number: 20140037739
    Abstract: Provided is a method for assessing cardiovascular risk in Metabolic Syndrome and Type 2 Diabetes patients. The method involves obtaining data from a Type 2 diabetes patient or a Metabolic Syndrome patient and determining a Fayad/Schentag index which includes a Glucose Supply Index (S) to an Insulin Demand Index (D) ratio.
    Type: Application
    Filed: January 30, 2013
    Publication date: February 6, 2014
    Applicant: THERASYN SENSORS, INC.
    Inventors: Jerome J. Schentag, Joseph M. Fayad, Scott V. Monte
  • Publication number: 20130237774
    Abstract: The present invention may be embodied as an ingestible device capable of sensing one or more chemical parameters. In use, the device can continuously determine the chemical concentrations within an alimentary canal tract. An embodiment of the device comprises a housing resistant to degradation by alimentary canal fluid, a light source, and image capture device. An analyte sensor is configured to obtain at least one measurement of a concentration of analyte in the fluid. The analyte sensor comprises a sensor substance in a sol-gel material so the sensor substance reversibly interacts with an analyte of interest. In addition, the analyte sensor is configured to generate a trigger signal for controlling the operation of subsystems in the device.
    Type: Application
    Filed: July 7, 2011
    Publication date: September 12, 2013
    Applicant: THERASYN SENSORS, INC.
    Inventors: Jerome J. Schentag, Frank V. Bright, David T. D'Andrea
  • Publication number: 20130225922
    Abstract: The present invention may be embodied as a retrievable device capable of sensing one or more properties of an individual (e.g., chemical or physical parameters, etc.) In use, the retrievable device can continuously determine the chemical concentrations within the vaginal tract. An embodiment of the retrievable device comprises a first housing having a light source and an image capture device, a second housing removably connected to the first housing and having a sensor, and a fitting for retrieving the device. The sensor may be an analyte sensor configured to obtain at least one measurement of a concentration of an analyte in a fluid. The analyte sensor comprises a sensor substance in a sol-gel material so the sensor substance reversibly interacts with an analyte of interest. In addition, the retrievable device can be configured to determine different physical parameters and re-implanted.
    Type: Application
    Filed: July 12, 2011
    Publication date: August 29, 2013
    Applicant: THERASYN SENSORS, INC.
    Inventors: Jerome J. Schentag, Frank V. Bright, David T. D'Andrea
  • Patent number: 8367418
    Abstract: The invention provides a method for determining a suitable drug combination for the treatment of Type 2 diabetes by obtaining data from a Type 2 diabetes population in which all of the Type 2 diabetics are not taking any Type-2 diabetes drugs and obtaining reference levels of glucose supply and insulin demand parameters. Data from discrete samples of Type 2 diabetes populations in which all individuals are being treated with one or more Type 2 diabetes drugs at a therapeutic dose are also obtained, and the effects of the drugs on the glucose supply and insulin demand parameters are used to determine adjustment factors which represent the effect of each of the drugs at the therapeutic dosage, which are used to determined a ratio of a Glucose Supply Index (S) to an Insulin Demand Index (D). The ratio is further utilized in scoring cardiovascular risks for Type 2 diabetics and recommending therapeutic interventions.
    Type: Grant
    Filed: October 25, 2010
    Date of Patent: February 5, 2013
    Assignee: TheraSyn Sensors, Inc.
    Inventors: Scott V. Monte, Frank Bright, Jerome Schentag